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Introduction 
In recent years, there has been a significant increase in the num-
ber of children and adolescents who are being treated with anti-
psychotic drugs. One survey in the US showed a six-fold increase 
in the number of prescriptions of antipsychotics for patients ≤20 
years from 1993–2002 (Olfson et al., 2006). The percentage of 
the user population accounted for by children and adolescents 
(i.e. by patients <18 years old) has doubled from 7% in 1996–
1997 to 15% in 2004–2005 (Domino and Swartz, 2008). Also, 
the annualized rate of any antipsychotic use per 1000 children 
increased from 0.78 (1999–2001) to 1.59 (2007) (Olfson et al., 
2010). Clinical studies demonstrate that atypical antipsychotics 
are effective for pediatric patients with early-onset schizophre-
nia and schizoaffective disorder, although they also cause more 
severe antipsychotic-related adverse side effects (e.g. extrapy-
ramidal side effects, sedation, prolactin elevation, weight gain) 
in pediatric patients than in adult patients (Findling et al., 2010; 
Kumra et al., 2008; Sikich et al., 2008). 
Current research on children and adolescent antipsychotic 
treatment has been mostly focusing on the efficacy, tolerabil-
ity, and side effect profiles of individual drugs. There is a general 
lack of research on the long-term consequences of antipsychotic 
treatment on the brain and behavioral development of patients. 
Preclinical studies suggest that synaptic connections, receptor 
densities — especially those among the dopamine and serotonin 
systems — in the prefrontal cortex, striatum, and hippocampus 
undergo dramatic maturational changes during adolescence that 
may have implications for understanding the unique clinical re-
sponse and side effects associated with adolescent antipsychotic 
treatment (Benes et al., 2000; Brenhouse and Andersen, 2011). 
Animal work also shows that antipsychotic exposure during ad-
olescence alters various neuroreceptors, including dopamine D1, 
D2 and D4 receptors (Moran-Gates et al., 2006), serotonin 5-HT1A 
and 5-HT2A receptors (Choi et al., 2010), and ionotropic gluta-
mate N-Methyl-D-aspartate (NDMA) and α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors (Choi et al., 
2009) in unique ways not seen in adult animals. All these findings 
strongly suggest that antipsychotic exposure during adolescence 
could alter the trajectory of the brain and behavioral develop-
ment of pediatric patients which in turn, may change their later 
response to drug treatment as adults. As pediatric treatment oc-
curs during the period of rapid brain and behavioral develop-
ment, there is a need to evaluate the possible short-term and 
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Abstract 
This study examined how repeated olanzapine (OLZ) or clozapine (CLZ) treatment in adolescence alters sensitivity to the same drug in adult-
hood in the phencyclidine (PCP) hyperlocomotion model. Male adolescent Sprague-Dawley rats (postnatal day (P) 44–48) were first treated 
with OLZ (1.0 or 2.0 mg/kg, subcutaneously (sc)) or CLZ (10.0 or 20.0 mg/kg, sc) and tested in the PCP (3.2 mg/kg, sc)-induced hyperloco-
motion model for five consecutive days. Then a challenge test with OLZ (0.5 mg/kg) or CLZ (5.0 mg/kg) was administered either during ad-
olescence (~P 51) or after the rats matured into adults (~P 76 and 91). During adolescence, repeated OLZ or CLZ treatment produced a per-
sistent inhibition of PCP-induced hyperlocomotion across the five test days. In the challenge test during adolescence, rats previously treated 
with OLZ did not show a significantly stronger inhibition of PCP-induced hyperlocomotion than those previously treated with vehicle (VEH). 
In contrast, those previously treated with CLZ showed a weaker inhibition than the VEH controls. When assessed in adulthood, the enhanced 
sensitivity to OLZ and the decreased sensitivity to CLZ were detected on ~P 76, even on ~P 91 in the case of OLZ. These findings suggest that 
adolescent OLZ or CLZ exposure can induce long-term alterations in antipsychotic response that persist into adulthood. 
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long-term impacts of antipsychotic medications on psychologi-
cal and brain functions in order to determine their risk/benefits. 
The present study examined the extent to which early anti-
psychotic exposure during adolescence affects “exposure-depen-
dent” alterations in responsiveness to its pharmacological ac-
tions later during adulthood. Such alterations can be manifested 
as either tolerance, which is characterized by progressive reduc-
tions in responsiveness to certain drug effects, or sensitization 
(also known as reverse-tolerance), which is characterized by pro-
gressive increases in responsiveness to certain drug effects (Car-
lezon et al., 2004). In recent years, we have demonstrated that, 
in adult rats, repeated treatment of olanzapine (OLZ) or clozap-
ine (CLZ) (two atypical antipsychotic drugs commonly used in 
the treatment of pediatric schizophrenic patients) (Almandil et 
al., 2011; Sikich et al., 2008) induces a potentiated (sensitization) 
or a decreased (tolerance) inhibition of the phencyclidine (PCP)-
induced hyperlocomotion, respectively (Feng et al., 2013; Sun 
et al., 2009; Zhang and Li, 2012; Zhao et al., 2012), a preclinical 
test for antipsychotic activity (Gleason and Shannon, 1997). The 
present study extended this line of research and investigated the 
persistence of OLZ sensitization and CLZ tolerance from adoles-
cence to adulthood in this model. Our general approach was to 
induce OLZ sensitization or CLZ tolerance during the adolescent 
period (postnatal day (P) 44–48) through repeated drug adminis-
tration (termed the induction phase), and then tested its expres-
sion either during adolescence (P 51) or during adulthood (P 76 
and P 91) (termed the expression phase). The alterations of an-
tipsychotic efficacy (sensitization or tolerance) were indexed by 
the change of the ability of OLZ or CLZ to suppress PCP-induced 
hyperlocomotion upon re-exposure in a challenge test. To as-
sess how adolescent antipsychotic treatment and PCP treatment 
affect the brain and behavioral functions and developments of 
adolescent rats, we also examined the prepulse inhibition (PPI) 
of acoustic startle response (ASR) periodically throughout their 
developmental period. PPI refers to the phenomenon of a reduc-
tion in the startle magnitude when the startling stimulus is pre-
ceded by a low-intensity prepulse. It measures the sensorimo-
tor gating ability which is found to be deficient in patients with 
schizophrenia and in animals treated with dopamine agonists 
and NMDA antagonists (Geyer and Braff, 1987; Li et al., 2011a, 
2011b; Swerdlow et al., 2008). 
Materials and methods 
Animals 
Male Sprague-Dawley adolescent rats weighing 101–125 g on 
the delivery date, (average age=P 35) (McCutcheon and Marinelli, 
2009) from Charles River Inc. (Portage, Michigan, USA) were used. 
They were housed two per cage, in 48.3×26.7×20.3 cm transpar-
ent polycarbonate cages under 12 h light/dark conditions (light on 
between 06:30–18:30 hours). Room temperature was maintained 
at 22 ±1°C with a relative humidity of 45–60%. Food and water 
was available ad libitum. Animals were allowed at least five days 
of habituation to the animal facility before being used in experi-
ments. All procedures were approved by the Institutional Animal 
Care and Use Committee at the University of Nebraska-Lincoln. 
Drugs and choice of dose 
The injection solution of phencyclidine hydrochloride (PCP, gift 
from National Institute on Drug Abuse Chemical Synthesis and 
Drug Supply Program) was obtained by mixing the drug with 
0.9% saline. The dose of PCP (3.2 mg/kg, sc) was chosen based 
on our previous work (Feng et al., 2013; Sun et al., 2009; Zhang 
and Li, 2012; Zhao et al., 2012). This dose of PCP is shown to 
induce a robust hyperlocomotion effect without causing se-
vere stereotypy (Gleason and Shannon, 1997; Kalinichev et al., 
2008). OLZ and CLZ (gifts from the National Institute of Mental 
Health drug supply program) were tested in this study because 
although they share some receptor-binding properties (e.g. do-
pamine D2, and serotonin 5-HT2A) they differ in several long-
term behavioral effects (Lieberman et al., 2008). They were dis-
solved in distilled sterile water with 1.0–1.5% glacial acetic acid. 
Two doses of OLZ (1.0 and 2.0 mg/kg) and CLZ (10.0 and 20.0 
mg/kg) were tested. These doses of OLZ and CLZ acutely inhibit 
PCP-induced hyperlocomotion (Feng et al., 2013; Li et al., 2010; 
Sun et al., 2009; Zhang and Li, 2012). Furthermore, both drugs at 
these doses give rise to a clinically comparable range (40%–80%) 
of striatal dopamine D2 occupancy in rats, which is comparable 
to values observed in schizophrenic patients (Kapur et al., 2003). 
All drugs were administrated subcutaneously (sc) at 1.0 ml/kg. 
Experiment 1: OLZ sensitization induced in 
adolescence and assessed in adolescence 
In this experiment, we examined the potential increased inhib-
itory effect of repeated OLZ treatment on the PCP-induced hy-
perlocomotion in adolescent rats. The entire experiment was 
comprised of the following two phases: the induction phase and 
OLZ challenge test (expression) phase. 
The induction phase. The apparatus was 16 motor activity 
monitoring boxes (48.3×26.7×20.3 cm transparent polycarbon-
ate cages) equipped with a row of six photocell beams (7.8 cm 
between two adjacent photobeams) placed 3.2 cm above the 
floor of the cage. A computer with recording software (Aero 
Apparatus Sixbeam Locomotor System v1.4, Toronto, Canada) 
was used to detect the disruption of the photocell beams and 
recorded the number of beam breaks. Twenty-four adolescent 
rats (~P 42–43) were first randomly assigned to one of four treat-
ment groups (n=6/ group) and one of 16 test boxes: vehicle 
(VEH)+VEH (sterile water+saline), VEH+PCP; OLZ 1.0+PCP and 
OLZ 2.0+PCP. On the first two days (~P 42–43), rats were handled 
for 2 min and habituated to the locomotor activity apparatus for 
30 min each day. On each of the next five consecutive days, ado-
lescent rats (~P 44– 48) were first injected with VEH (sterile wa-
ter), OLZ 1.0 mg/kg, or OLZ 2.0 mg/kg, and then immediately 
placed in the boxes for 30 min. At the end of the 30-minute pe-
riod, they were taken out and injected with PCP (3.2 mg/kg, sc) 
or saline and placed back in the boxes for another 60 min. Mo-
tor activity was measured in 5 min intervals throughout the en-
tire 90-minute testing session. 
The challenge test (expression phase) on ~P 51. Two days 
after the last OLZ test, all rats were returned to the locomotor 
activity boxes for one re-habituation session (30 min) (~P 50), 
followed by the OLZ sensitization test one day later (~P 51). On 
the challenge test day, all rats were first injected with a small 
dose of OLZ 0.5 mg/kg and then immediately placed in the mo-
tor activity boxes for 30 min. At the end of the 30-minute pe-
riod, rats were taken out and injected with PCP (3.2 mg/kg) and 
placed back in the boxes for another 60 min. Motor activity was 
recorded for the entire 90-minute testing session.  
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Experiment 2: CLZ tolerance induced in adolescence 
and assessed in adolescence 
In this experiment, we examined the effects of repeated CLZ 
treatment on PCP-induced hyperlocomotion during adolescence. 
The basic procedure was identical to that of Experiment 1 with 
the exceptions that twenty four adolescent rats were treated with 
two doses of CLZ (10.0 and 20.0 mg/kg, sc) during the induction 
phase and CLZ 5.0 mg/kg was used in the CLZ challenge test 
(~P 51). The four groups were: VEH+VEH (sterile water+saline), 
VEH+PCP (sterile water+PCP 3.2 mg/kg, sc), CLZ 10+PCP (CLZ 
10.0 mg/kg+PCP 3.2 mg/kg), and CLZ 20+PCP (CLZ 20.0 mg/ 
kg+PCP 3.2 mg/kg). 
Experiment 3: OLZ sensitization induced in adoles-
cence and assessed in adulthood 
In this experiment, we examined the potential long-lasting OLZ 
sensitization from adolescence to adulthood. The entire exper-
iment was comprised of the following three components: The 
induction phase in adolescence, OLZ challenge tests in adult-
hood, and PPI assessment. Table 1 details the timeline of events. 
The induction phase in adolescence. Twenty-four adolescent 
rats (~P 42–43) were subjected to two days of apparatus ha-
bituation and five days of repeated OLZ drug testing (VEH, 1.0 
mg/kg, or 2.0 mg/kg) under either PCP (3.2 mg/kg, sc) or saline. 
OLZ challenge tests in adulthood on ~P 76 and 91. Twenty-
nine days after the last PCP test, after the rats became adults 
(~P 75) (McCutcheon and Marinelli, 2009), they were returned 
to the locomotor activity boxes for one re-habituation session 
(30 min), followed by the first OLZ sensitization challenge test 
one day later (~P 76). The basic procedure was similar to that 
detailed in Experiment 1 with the exception that rats from the 
VEH+VEH group received a double injection of sterile water and 
saline. The second sensitization challenge test was conducted on 
~P 91 in which all rats were first injected with OLZ 0.5 mg/kg, 30 
min later, an injection of PCP 3.2 mg/kg. 
PPI assessment. The PPI test apparatus and procedure have 
been described in detail previously (Chen et al., 2011; Li et al., 
2011a, 2011b; Qiao et al., 2013). A total of three PPI tests were 
conducted throughout the developmental period. The first one 
was done during the late adolescent period (~P 49, one day after 
the five drug test days), the second one during the early adult-
hood period (~P 67). The third one (~P 77) was conducted one 
day after the 1st sensitization test. Each session lasted approx-
imately 18 min and began with a 5-min period of 70 dB back-
ground noise (which continued throughout the duration of the 
session) followed by four different trial types: PULSE ALONE tri-
als and three types of PREPULSE + PULSE trials, which consisted 
of a 20 ms 73, 76, or 82 dB prepulse (3, 6, and 12 dB above back-
ground) followed 100 ms later by a 120 dB pulse (40 ms). Each 
session was divided into four blocks. Blocks 1 and 4 were iden-
tical, each consisting of four PULSE ALONE trials. Blocks 2 and 
3 were also identical and each consisted of eight PULSE ALONE 
trials and five of each PREPULSE + PULSE trial type. A total of 54 
trials were presented during each test session. Trials within each 
block were presented in a pseudorandom order and were sepa-
rated by a variable intertrial interval averaging 15 s (ranging from 
9–21 s). Startle magnitude was defined as the maximum force 
(measured in Newtons) applied by the rat to the startle appara-
tus recorded over a period of 100 ms beginning at the onset of 
the pulse stimulus. Between each stimulus trial, 100 ms of ac-
tivity was recorded when no stimulus was present: these trials 
were called NOSTIM trials and were not included in the calcula-
tion of intertrial intervals. Responses recorded during NOSTIM 
trials are considered a measure of gross motor activity within the 
PPI boxes. Startle responses from testing blocks 2 and 3 were 
used to calculate percentage prepulse inhibition (%PPI) for each 
acoustic prepulse trial type: 
                                average startle response to
   
%PPI = 100 −
 [ (     PREPULSE + PULSE trials   ) × 100 ]                                average startle response to 
                                     PULSE ALONE trials 
Table 1. Timeline of events in experiments 3 and 4. 
Days of study  Approximate age  Manipulation 
1–2  P 42–43  Habituation to the motor activity boxes 
3–7  P 44–48  Five days of drug testing 
8  P 49  1st PPI test 
9–26  P 50–66  Rest 
27  P 67  2nd PPI test 
28–35  P 68–74  Rest 
36  P 75  Habituation to the motor activity boxes 
37  P 76  1st drug challenge test: OLZ 0.5 mg/kg or CLZ 5.0 mg/kg followed by PCP 3.2 mg/kg   
(except the VEH+VEH group) 
38  P 77  3rd PPI test 
39–50  P 78–89  Rest 
51  P 90  Habituation to the motor activity boxes 
52  P 91  2nd drug challenge test: OLZ 0.5 mg/kg or CLZ 5.0 mg/kg followed by PCP 3.2 mg/kg 
CLZ: clozapine; OLZ: olanzapine; P: postnatal day; PCP: phencyclidine; PPI: prepulse inhibition; VEH: vehicle.  
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Experiment 4: CLZ tolerance induced in adolescence 
and assessed in adulthood 
This experiment examined whether the tolerance effect induced 
by repeated CLZ treatment to adolescent rats in the PCP model 
persisted into adulthood. The basic procedure was identical to 
that of Experiment 3 with the exception that CLZ (10.0 and 20.0 
mg/ kg, sc) instead of OLZ, were administered during the ado-
lescent period and one challenge dose of CLZ (5.0 mg/kg) was 
tested during the challenge tests (see Table 1). The four groups 
(n=6/group) were: VEH+VEH (sterile water+saline), VEH+PCP; 
CLZ 10.0+PCP and CLZ 20.0+PCP. 
Statistical analysis 
Motor activity data from the five consecutive drug test days 
were expressed as mean values ±standard error of the mean 
(SEM) and analyzed using a mixed-design analysis of variance 
(ANOVA) with the between-subjects factor being drug group and 
the within-subjects factor being test day, followed by Fisher’s 
least significant difference (LSD) tests to examine group differ-
ence. Data from the challenge tests were analyzed by one-way 
ANOVA followed by Fisher’s LSD (for more than three groups). 
%PPI data were analyzed using repeated measures ANOVAs with 
drug treatment group as a between-subjects factor and prepulse 
level as a within-subjects factor. All analyses were conducted us-
ing IBM SPSS Statistics 19, and p<0.05 was considered statisti-
cally significant. 
Results 
Experiment 1: OLZ sensitization induced in adoles-
cence and assessed in adolescence 
The induction phase. Figure 1(a) shows the mean motor ac-
tivity of the four groups of rats during the 30-minute test pe-
riod before PCP or vehicle injection throughout the five days 
Figure 1. Effect of repeated olanzapine (OLZ) (1.0 and 2.0 mg/kg) treatment on phencyclidine (PCP)-induced hyperlocomotion across the initial five 
test days (n=6/group) from ~postnatal day (P) 44–48 and on the re-habituation day (~P 50) and challenge test day (~P 51). (a) Locomotor activity 
during the 30-minute test period before vehicle (VEH) or PCP injection and (b) 60 min after PCP or VEH injection across the five test days is expressed 
as mean+standard error of the mean (SEM) for each group. (c) Locomotor activity measured for 30 min on the re-habituation day. On the OLZ chal-
lenge test day on ~P 51, locomotor activity was measured during the 30-minute test period before PCP injection (d) and during the 60-minute test 
period after PCP injection (e). * p<0.05 relative to the VEH+VEH group; # p<0.05 relative to the VEH+PCP group.  
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of drug testing. Two-way repeated measures ANOVA revealed 
a main effect of group, F(3,20)=7.346, p=0.002 and test day, 
F(4,80)=22.952, p<0.001. Post-hoc Fisher’s LSD tests revealed 
that the two OLZ groups had significantly lower motor activity 
than the VEH+PCP group, all ps<0.03, confirming the inhibitory 
effect of OLZ treatment on spontaneous motor activity. 
Figure 1(b) shows the mean motor activity during the 60-min-
ute test period after PCP or VEH injection. Once again, two-
way repeated measures ANOVA revealed a main effect of group, 
F(3,20)=40.817, p<0.001, and a significant group×day interac-
tion, F(12,80)=2.910, p=0.002. The VEH+PCP group had signifi-
cantly higher motor activity than the VEH+VEH group, p<0.001, 
indicating a strong psychomotor activation effect of this dose of 
PCP. The two OLZ groups had significantly lower motor activity 
than the VEH+PCP group, ps<0.001, confirming the inhibitory 
effect of OLZ treatment on PCP-induced hyperlocomotion. This 
inhibition was not complete though, as both OLZ groups still 
had significantly higher locomotion than the VEH+VEH group, 
ps<0.042. 
Re-habituation session. On the re-habituation day (Figure 
1(c)), rats previously treated with OLZ showed much higher 
motor activity than the other groups (a main effect of group, 
F(3,20)=11.755, p<0.001, and ps<0.005 vs the VEH groups), sug-
gesting a possibly compensatory rebound effect against the mo-
tor inhibitory effect of OLZ during the drug withdrawal. 
OLZ challenge test on ~P 51. One way ANOVA found no 
main effect of group in the 30-minute period before the PCP 
injection, F(3,20)=1.533, p=0.237 (Figure 1(d)). In the 60-min-
ute test period after the PCP injection (Figure 1(e)), the main 
effect of group was also not significant, F(3,20)=1.879, p=0.166, 
although the OLZ 2.0+PCP group did show a relatively lower 
motor activity than the VEH+PCP group. These results suggest 
that repeated OLZ treatment caused a strong sensitized inhi-
bition of PCP-induced hyperlocomotion during the drug test 
phase (i.e. the induction phase). However, the expression of 
such a sensitization effect three days later (still in adolescence) 
was relatively weak. 
Experiment 2: CLZ tolerance induced in adolescence 
and assessed in adolescence 
The induction phase. In the 30-minute test period through-
out the five days of drug testing (Figure 2(a)), the effect of 
test day, F(4,80)=23.096, p<0.001, and the group×day inter-
action, F(12,80)=2.053, p=0.030 were significant, but the ef-
fect of group was not, F(3,20)=1.656, p=0.208. In the 60-min-
ute period after PCP or VEH injection (Figure 2(b)), there was 
a main effect of group, F(3,20)=25.057, p<0.001, but no main 
effect of test day, F(4,80)=0.994, p=0.416, nor group×day in-
teraction, F(12,80)=1.711, p=0.08. Post-hoc tests revealed that 
the VEH+PCP group had significantly higher motor activity 
than the VEH+VEH group, p<0.001. The CLZ 10+PCP group 
had significantly lower motor activity relative to the VEH+PCP 
group, p<0.001, but higher activity than the VEH+VEH group, 
p=0.038. In contrast, the CLZ 20+PCP group only showed 
significantly lower motor activity than the VEH+PCP group, 
p<0.001, but not than the VEH+VEH group, p=0.182. These 
results suggest that CLZ at 20.0 mg/kg, but not at 10.0 mg/
kg completely abolished the motor activation effect of PCP 
and this inhibitory effect of CLZ maintained throughout the 
five days of testing. 
Re-habituation session. Similar to the OLZ rats in Experi-
ment 1, rats previously treated with CLZ (10.0 and 20.0 mg/
kg) showed much higher motor activity than the other groups 
(Figure 2(c)). One-way ANOVA showed a significant effect of 
group, F(3,20)=5.025, p=0.009. Post-hoc test showed that the 
two CLZ groups had significantly higher motor activity than 
the VEH+PCP group, all ps<0.017, and the CLZ 20+PCP group 
also showed significantly higher motor activity relative to the 
VEH+VEH group, p=0.027, indicating a possibly compensatory 
rebound effect against the motor inhibitory effect of CLZ dur-
ing the drug withdrawal. 
CLZ challenge test on ~P 51. Figure 2(d) shows the mean 
motor activity during the 30-minute test period on the CLZ tol-
erance test on ~P 51. One-way ANOVA found a main effect of 
group, F(3,20)=3.386, p=0.038 due to the higher motor activity 
in the CLZ 20+PCP group, ps<0.015. 
One-way ANOVA on the motor activity in the 60-minute 
test period after PCP injection found a main effect of group, 
F(3,20)=3.859, p=0.025. Again, the CLZ 20+PCP group had sig-
nificantly higher motor activity than the CLZ naive groups (i.e. 
the VEH+VEH group, p=0.006 and the VEH+PCP group, p=0.013) 
(Figure 2(e)). 
Overall, results from this experiment suggest that repeated 
CLZ treatment caused a persistent inhibition of PCP-induced hy-
perlocomotion during the induction phase in a dose-dependent 
fashion. Such a treatment caused a tolerance in the inhibition of 
PCP-induced hyperlocomotion later on. 
Experiment 3: OLZ sensitization induced in adoles-
cence and assessed in adulthood 
The induction phase in adolescence. Figure 3(a) shows the 
mean motor activity of the four groups of rats during the 
30-minute period before PCP or VEH injection throughout the 
five days of drug testing. Repeated measures ANOVA revealed 
a main effect of group, F(3,20)=6.174, p=0.004, and a main ef-
fect of test day, F(4,80)=18.767, p<0.001. Post-hoc analysis re-
vealed that the two OLZ groups had significantly lower motor 
activity than the VEH+VEH group, ps<0.003. The OLZ (1.0 mg/
kg) group also had significantly lower motor activity than the 
VEH+PCP group, p=0.029, confirming the strong inhibitory ef-
fect of OLZ on spontaneous motor activity. 
During the 60-minute period after PCP or VEH injection 
(Figure 3(b)), there was a significant main effect of group, 
F(3,0)=45.186, p<0.001, and a significant group×day inter-
action, F(12,80)=5.037, p<0.001. Post-hoc LSD tests revealed 
that the two OLZ (1.0 and 2.0 mg/kg) groups showed signifi-
cantly lower motor activity compared to the VEH+PCP group, 
ps<0.001. The VEH+VEH group had significantly lower motor 
activity than the VEH+PCP group, p<0.001, the OLZ 1.0+PCP 
group, p<0.001, and marginally different from the OLZ 2.0+PCP 
group, p=0.05, indicating that the inhibition by OLZ was 
not completely lowered to the VEH level. The OLZ 2.0+PCP 
group also had significantly lower motor activity than the OLZ 
1.0+PCP group, p<0.001.  
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Re-habituation session on ~P 75 and 90. On the 1st re-ha-
bituation day (~P 75), rats previously treated with OLZ showed 
much higher motor activity than the other groups (Figure 
4(a)). One-way ANOVA showed a significant effect of group, 
F(3,20)=4.308, p=0.017. Post-hoc tests showed that the OLZ 
2.0+PCP group had significantly higher motor activity than the 
VEH+PCP and OLZ 1.0+PCP groups, all ps<0.008. Similarly on 
the 2nd re-habituation day (~P 90), the OLZ 2.0+PCP group 
still had significantly higher motor activity than the VEH+VEH 
group, p=0.033 and the VEH+PCP group, p=0.015. The OLZ 
1.0+PCP group also had significantly higher motor activity than 
the VEH+PCP group, p=0.039 (Figure 5(a)). These results indi-
cate a long-lasting compensatory rebound effect of adoles-
cent OLZ treatment against the motor inhibitory effect of OLZ 
in adulthood. 
OLZ challenge tests in adulthood on ~P 76 and 91. Figure 
4(b) shows the mean motor activity of the four groups of rats 
in the 1st 30-minute test period on the 1st OLZ challenge test. 
One way ANOVA revealed a main effect of group, F(3,20)=3.586, 
p=0.032. Post-hoc two group comparisons revealed that the OLZ 
1.0+PCP group had significantly lower motor activity than the 
OLZ naive groups, all ps<0.022. One way ANOVA on the motor 
activity data in the 60-minute test period after PCP injection also 
revealed a main effect of group, F(3,20)=20.125, p<0.001. Again, 
the two OLZ-treated groups had significantly lower motor activ-
ity than the VEH+PCP, ps<0.002, indicating the OLZ sensitization 
effect (Figure 4(b) and 4(c)). 
On the 2nd OLZ challenge test, one rat from the OLZ 
2.0+PCP group jumped out the testing box, and its data were 
not used in the subsequent data analysis. The group effect in 
the first 30-minute test period was not significant (Figure 5(b)), 
F(3,19)=1.965, p=0.154, but the group effect in the second 
60-minute test period was significant, F(3, 19)=5.110, p=0.009 
(Figure 5(c)). Post-hoc two group comparisons revealed that both 
the OLZ 1.0+PCP and OLZ 2.0+PCP groups had significantly 
Figure 2. Effect of repeated clozapine (CLZ) (10.0 and 20.0 mg/kg) treatment on phencyclidine (PCP)-induced hyperlocomotion across the initial five 
test days (n=6/group) from ~postnatal day (P) 44–48 and on the re-habituation day (~P 50) and challenge test day (~P 51). (a) Locomotor activity in 
the 30 min before vehicle (VEH) or PCP injection and (b) 60 min after PCP or VEH injection across the five test days is expressed as mean+standard 
error of the mean (SEM) for each group. (c) Locomotor activity measured for 30 min on the re-habituation day. On the CLZ challenge test day on ~P 
51, locomotor activity was measured during the 30-minute test period before PCP injection (d) and during the 60-minute test period after PCP in-
jection (e). * p<0.05 relative to the VEH+VEH group; # p<0.05 relative to the VEH+PCP group.  
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lower motor activity than the VEH+PCP group, p=0.005, and 
p=0.002, respectively, a finding similar to that observed on ~P 
76. The VEH+PCP group still had significantly higher motor activ-
ity than the VEH+VEH group, p=0.023, indicating the persistence 
of PCP sensitization effect which was not abolished by acute OLZ 
treatment. Furthermore, the finding that both OLZ groups did 
not differ significantly from the VEH+VEH, ps>0.259, suggests 
that the OLZ sensitization effect reached a level high enough to 
eliminate the PCP sensitization effect. 
Overall, results from this experiment suggest that repeated 
OLZ treatment during adolescence induced a strong sensiti-
zation effect during the adolescent treatment period and that 
this sensitization effect persisted into adulthood. This effect 
was long-lasting and dose-dependent. It manifested itself as 
an enhanced inhibition of PCP-induced hyperlocomotion (an 
index of antipsychotic activity) in the OLZ treated animals, and 
a rebound of spontaneous motor activity under the drug-free 
condition. 
PPI assessment. PPI data from the three time points of testing 
(~P 49, 67 and 77) did not reveal any significant group differ-
ence, p=0.957, 0.708, and 0.286, respectively (data not shown). 
The group×prepulse level interactions were also not significant, 
p=0.447, 0.179, and 0.159, respectively. These findings suggest 
that repeated OLZ treatment and PCP treatment did not signif-
icantly impair the sensorimotor gating ability.  
Figure 3. Effect of repeated olanzapine (OLZ) (1.0 and 2.0 mg/kg) treatment on phencyclidine (PCP)-induced hyperlocomotion across the five test 
days (n=6/group) during adolescence. (a) Locomotor activity in the 30 min before vehicle (VEH) or PCP injection and (b) 60 min after PCP or VEH 
injection across the five test days is expressed as mean+standard error of the mean (SEM) for each group. * p<0.05 relative to the VEH+VEH group; 
# p<0.05 relative to the VEH+PCP group; & p<0.05 relative to the OLZ 1.0+PCP group.  
Figure 4. Locomotor activity on (a) the 1st re-habituation day (~postnatal day (P) 75) and (b) 1st olanzapine (OLZ) challenge day during the 30-min-
ute test period before phencyclidine (PCP) or saline injection and (c) the 60-minute test period after PCP or vehicle (VEH) injection (~P 76). *p<0.05 
relative to the VEH+VEH group; #p<0.05 relative to the VEH+PCP group.  
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Experiment 4: CLZ tolerance induced in adolescence 
and assessed in adulthood 
The induction phase in adolescence. Figure 6(a) shows the 
mean locomotor activity of the four groups of rats during the 
30-minute period before PCP or VEH injection throughout the 
five days of drug testing. Two-way repeated measures ANOVA 
revealed a main effect of group, F(3, 20)=5.321, p=0.007, test 
day, F(4,80)=7.781, p<0.001, and a significant group×day inter-
action, F(12,80)=2.033, p=0.032. Post-hoc LSD tests revealed that 
the VEH+VEH group had significantly higher motor activity than 
the CLZ 10+PCP group, p=0.005, and the CLZ 20+PCP group, 
p=0.002, indicating a strong motor inhibition by CLZ. 
During the 60-minute period after PCP or VEH injection (Fig-
ure 6(b)), two-way repeated measures ANOVA revealed a sig-
nificant main effect of group, F(3,20)=49.740, p<0.001, a sig-
nificant main effect of test day, F(4,80)=4.604, p=0.002, and a 
significant group×day interaction, F(12,80)=8.875, p<0.001. The 
two CLZ groups had significantly lower motor activity than the 
VEH+PCP group, all ps<0.001, confirming the strong inhibitory 
effect of CLZ treatment on PCP-induced hyperlocomotion. The 
VEH+VEH group showed significantly lower motor activity than 
the VEH+PCP group, p<0.001, the CLZ 10+PCP group, p<0.001, 
and the CLZ 20+PCP group, p=0.017, indicating the inhibition 
by CLZ was not completely back to the VEH level.  
Figure 5. Locomotor activity on (a) the 2nd re-habituation day (~postnatal day (P) 90) and (b) 2nd olanzapine (OLZ) challenge day during the 30-min-
ute test period before phencyclidine (PCP) injection and (c) the 60-minute test period after PCP injection (~P 91). * p<0.05 relative to the VEH+VEH 
group; # p<0.05 relative to the VEH+PCP group.  
Figure 6. Effect of repeated clozapine (CLZ) (10.0 and 20.0 mg/kg) treatment on phencyclidine (PCP)-induced hyperlocomotion across the five test 
days (n=6/group) during adolescence. (a) Locomotor activity in the 30 min before vehicle (VEH) or PCP injection and (b) 60 min after PCP or VEH 
injection across the five test days is expressed as mean+standard error of the mean (SEM) for each group. * p<0.05 relative to the VEH+VEH group; 
# p<0.05 relative to the VEH+PCP group.  
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Re-habituation session on ~P 75 and 90. On the 1st re-ha-
bituation day, rats previously treated with CLZ showed much 
higher motor activity than the other groups (Figure 7(a)). One-
way ANOVA confirmed this observation, F(3,20)=3.204, p=0.045. 
Post-hoc tests showed that the CLZ 20+PCP group had signif-
icantly higher motor activity than the VEH+VEH and VEH+PCP 
groups, ps<0.033. On the 2nd re-habituation day (~P 90), one 
day before the second CLZ tolerance test, this compensatory re-
bound effect disappeared, as there was no main effect of group, 
F(3,20)=0.532, p=0.665 (Figure 8(a)). 
CLZ challenge tests in adulthood on ~P 76 and 91. Figure 
7(b) shows the mean motor activity of the four groups of rats in 
the first 30-minute test period on the 1st CLZ challenge test. No 
significant group effect was found, F(3,20)=1.083, p=0.379. How-
ever, the significant group effect was found in the 60-minute test 
period after PCP injection (Figure 7(c)), F(3,20)=9.785, p<0.001. 
The CLZ 10+PCP group (but not the CLZ 20+PCP group) had 
significantly higher motor activity than the VEH+PCP group, 
p=0.019, indicating the CLZ tolerance effect. The CLZ groups 
also had significantly higher motor activity than the VEH+VEH 
group, all ps<0.018. On the 2nd challenge test (Figure 8(b) and 
8(c)), the group effect was not significant, all ps>0.623. 
Overall, results from this experiment suggest that, like OLZ, 
repeated CLZ treatment induced a sensitized inhibition of PCP-
induced hyperlocomotion during the adolescent drug treatment 
Figure 7. Locomotor activity on (a) the 1st re-habituation day (~postnatal day (P) 75) and (b) 1st clozapine (CLZ) challenge day during the 30-min-
ute test period before phencyclidine (PCP) injection and (c) the 60-minute test period after PCP or vehicle (VEH) injection (~P 76). * p<0.05 relative 
to the VEH+VEH group; # p<0.05 relative to the VEH+PCP group.  
Figure 8. Locomotor activity (a) on the 2nd re-habituation day (~postnatal day (P) 90) and (b) 2nd clozapine (CLZ) challenge day during the 30-min-
ute test period before phencyclidine (PCP) injection and (c) the 60-minute test period after PCP injection (~P 91).    
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period. When assessed in adulthood, a tolerance effect (i.e. de-
creased inhibition of the PCP-induced hyperlocomotion) was 
still detected. 
PPI assessment. PPI data from the three time points of testing 
(~P 49, 67, and 77) did not reveal any significant group differ-
ence, p=0.286, 0.239, and 0.789, respectively (data not shown). 
The group×prepulse level interactions were also not significant, 
p=0.644, 0.088, and 0.232, respectively. These findings suggest 
that repeated CLZ treatment and PCP treatment did not signif-
icantly impair the sensorimotor gating ability. 
Discussion 
The present study uncovered an important phenomenon, that 
is, adolescent antipsychotic exposure can induce long-lasting 
alterations in the behavioral development of animals which, in 
turn, cause an increase or decrease of their later antipsychotic 
response as adults. Specifically, we showed that adolescent OLZ 
treatment induced a sensitization effect that persisted through-
out the development into adulthood. This effect was long-last-
ing, detectable even more than 40 days since the last drug treat-
ment. It was dose-dependent and manifested as an enhanced 
inhibition of PCP-induced hyperlocomotion (a validated mea-
sure of antipsychotic activity) and a rebound of spontaneous 
motor activity. In contrast, although adolescent CLZ treatment, 
like OLZ, induced a persistent inhibition of PCP-induced hyper-
locomotion during the drug treatment period and caused an 
increase in spontaneous motor activity, when assessed for its 
short-term (i.e. three days) and long-term (i.e. >30 days) conse-
quences, a decreased inhibition of PCP-induced hyperlocomo-
tion (i.e. tolerance) was noticed in CLZ-pretreated rats, and this 
effect persisted into early adulthood but disappeared with the 
passage of time. In this regard, CLZ shares a similar inhibitory 
effect with OLZ during drug treatment (i.e. the induction phase) 
and drug withdrawal periods. However, CLZ differed from OLZ 
in the drug challenge test (i.e. the expression phase) in which a 
tolerance, rather than a sensitization effect was found. 
The PCP-induced hyperlocomotion model is commonly used 
as a screening tool for the detection of antipsychotic activity. 
When given acutely, many antipsychotics inhibit the hyperloco-
motor activity induced by acute administrations of PCP (Glea-
son and Shannon, 1997; Millan et al., 1999; Sun et al., 2010). In 
recent years, we have used the repeated PCP hyperlocomotion 
model to investigate the long-term effects of repeated antipsy-
chotic treatment (Feng et al., 2013; Sun et al., 2009, Zhang and 
Li, 2012, Zhao et al., 2012). We and others show that in adult 
rats, repeated haloperidol, OLZ or CLZ treatment, but not anx-
iolytic (e.g. chlordiazepoxide) or antidepressant treatment (e.g. 
fluoxetine and citalopram), progressively potentiates the inhibi-
tion of PCP-induced hyperlocomotion across sessions and pro-
longs this action within sessions (Redmond et al., 1999; Sun et 
al., 2009; Zhao et al., 2012). When the long-term effects were as-
sessed in a challenge test later, adult rats previously treated with 
OLZ showed an enhanced response to OLZ (i.e. sensitization), 
while those previously treated with CLZ showed a decreased re-
sponse (i.e. tolerance) (Feng et al., 2013). The present study ex-
tended our adult work to adolescent animals by showing that 
even adolescent rats exhibited drug-induced alterations in an-
tipsychotic response and these alterations were long-lasting. 
These significant findings are consistent with our recent study 
showing that OLZ sensitization and CLZ tolerance could be in-
duced in adolescent rats in the conditioned avoidance response 
model (Qiao et al., 2013), another animal test of antipsychotic 
activity, suggesting the generality of these long-term antipsy-
chotic effects independent of any particular behavioral model 
used to assess these effects. 
Another noticeable manifestation of long-term consequences 
of adolescent OLZ or CLZ treatment was the rebound of spon-
taneous motor activity on the re-habituation days when all rats 
were tested drug-free and presumably in the drug withdrawal 
state. Rats treated with OLZ or CLZ were more active than those 
treated with VEH or even PCP. This effect was also dose-depen-
dent and persisted from adolescence into adulthood. Interest-
ingly, although repeated OLZ and CLZ gave rise to opposite 
effects (sensitization vs tolerance) on the inhibition of PCP-in-
duced hyperlocomotion on the challenge tests, they all caused 
the same rebound effect on spontaneous motor activity. We are 
not aware of any previous report on this phenomenon. It resem-
bles to some extent the antipsychotic withdrawal-induced be-
havioral hypersensitivity; a state of dopamine supersensitivity 
that is characterized by increased behavioral responses to the 
psychomotor-stimulating effects of dopamine agonists such as 
amphetamine or apomorphine thought to result from hypersen-
sitivity of dopamine D2 receptors (especially in a state of high-
affinity, D2 high) (Carvey et al., 1990; Kinon et al., 1984; Samaha 
et al., 2007; Sayers et al., 1975; Seeman, 2006). This issue needs 
to be further investigated to determine its clinical relevance and 
related mechanisms. 
One seemingly strange finding was that the expression of 
OLZ sensitization appeared to be weaker in adolescence than 
in adulthood. This effect was almost non-detectable just three 
days after the last OLZ treatment, while it was robustly expressed 
at a time point more than 40 days since the last OLZ treatment. 
With this perspective, the strength of OLZ sensitization actually 
increased over time. This observation fits well with the descrip-
tion of “time-dependent sensitization,” referring to the observa-
tion that a brief exposure to an antipsychotic drug induces a clin-
ical effect that grows with the passage of time (Antelman et al., 
2000). In Antelman’s earlier work, he found that a single expo-
sure to a clinically low dose of antipsychotic produced changes 
that were shown up to eight weeks later (Antelman, 1986). The 
strengthening of OLZ sensitization effect over time has also been 
reported in adult rats in the conditioned avoidance response 
model (Swalve and Li, 2012). On the other hand, CLZ tolerance 
appeared to be weakened with the passage of time, suggesting 
that the drug memory mechanisms involved in CLZ tolerance 
may degrade over time (i.e. forgetting). The significance of this 
temporal difference between OLZ and CLZ effects may warrant 
further research. 
Besides, in the PCP-induced hyperlocomotion test, OLZ sensi-
tization has also been reported in other tests, such as the condi-
tioned avoidance response test (Swalve and Li, 2012; Zhang and 
Li, 2012), the prepulse inhibition of acoustic startle procedure (Li 
et al., 2011) and the operant responding procedure (Varvel et al., 
2002), although the term “OLZ sensitization” may not have been 
used. Similarly, CLZ-induced tolerance has also been observed 
in other tasks, including the drug discrimination task (Goudie 
et al., 2007a, 2007b) and conditioned avoidance response test 
(Li et al., 2010, 2012; Sanger, 1985). Among many antipsychotic 
drugs, CLZ appears to be the only one that causes a tolerance, 
rather than a sensitization effect. Another difference between 
OLZ and CLZ was that CLZ tolerance seems to be weaker than 
A precl inical  test  in the phencycl id ine hyperlocomotion model   373
OLZ sensitization in terms of its persistence. While OLZ sensiti-
zation was detected at both adulthood test time points (~P 76 
and ~P 91), CLZ tolerance was only detectable on ~P 76. One 
caveat to this conclusion is that the 1st CLZ challenge on ~P 76 
might have affected the 2nd CLZ challenge on ~P 91 differently 
from that of the 1st OLZ challenge on the 2nd OLZ challenge, 
leading to the persistence of OLZ sensitization and the disap-
pearance of CLZ tolerance on ~P 91. Because we did not test 
these effects in animals not previously challenged on ~P 76, we 
could not determine the exact causes of this time course OLZ–
CLZ difference. If this difference reflects the superior therapeu-
tic effect and favorable side effects of CLZ, understanding the 
underlying mechanisms may help us develop and identify CLZ-
like drugs, as CLZ appears to be more effective than OLZ and 
haloperidol in the treatment of childhood onset schizophrenia 
(Kumra et al., 2008). 
In this study, we also assessed how adolescent antipsychotic 
and PCP treatments affected the PPI performance, a measure of 
the sensorimotor gating ability which is found to be deficient in 
patients with schizophrenia and in animals treated with dopa-
mine agonists and NMDA antagonists (Geyer and Braff, 1987; Li 
et al., 2011a, 2011b; Swerdlow et al., 2008). We did not find any 
long-lasting detrimental effect by repeated OLZ or CLZ treat-
ment. This result is consistent with our recent adolescence anti-
psychotic study using another animal model of antipsychotic ac-
tivity (Qiao et al., 2013) and others (Llorente-Berzal et al., 2012; 
Meyer et al., 2010). Other PCP studies show that PPI in rats is 
disrupted during, but not after, chronic PCP-treatment (Marti-
nez et al., 1999; Schwabe et al., 2005), suggesting that there is a 
dissociation between the brain neurochemical effects of chronic 
PCP treatment and its behavioral effects (Jentsch et al., 1998). 
It is also possible that in order to reveal any long-lasting effect 
of adolescent antipsychotic treatment and PCP effects in adult-
hood, we need to challenge the animals with either a dopamine 
agonist or an NMDA antagonist. This work is certainly warranted. 
What are the neurobiological mechanisms that account for 
OLZ sensitization and CLZ tolerance as observed in this study? 
Because various neuroreceptors targeted by antipsychotic drugs, 
such as dopaminergic, adrenergic, serotonergic receptors, un-
dergo dramatic changes from the adolescent period to adult-
hood (e.g. an inverted U-shape curve of development) (Ander-
sen et al., 2000; Lidow et al., 1991; Tarazi et al., 1998; Teicher et 
al., 1995), it is possible that antipsychotic exposure in adoles-
cence may alter the expression and function of these neurore-
ceptors (Choi et al., 2009, 2010; Moran-Gates et al., 2006) which 
“imprint” an antipsychotic drug memory trace (Li et al., 2007). 
The finding that OLZ sensitization and CLZ tolerance had sur-
vived the adolescent brain re-organization period (Brenhouse 
and Andersen, 2011) indicates that certain drug-induced brain 
changes may be relatively permanent. We recently investigated 
the neurochemical basis of OLZ sensitization and CLZ tolerance 
in adult rats. Our results suggest that dopamine D2/3 receptors 
and serotonin 5-HT2A/2C receptors may play a role in these effects 
(Li et al., 2010). Using a conditioned avoidance response model, 
another animal model of antipsychotic activity (Wadenberg and 
Hicks, 1999), we found that pretreatment of quinpirole, a selec-
tive D2/D3 dopaminergic receptor agonist, attenuated OLZ sen-
sitization but enhanced CLZ tolerance. The likely brain sites in-
clude various limbic structures, such as the nucleus accumbens 
(NAc) shell, ventral tegmental area (VTA), ventral part of lateral 
septal nucleus (LSv), central amygdaloid nucleus (CeA), and me-
dial prefrontal cortex (mPFC) (Zhao et al., 2012). In this regard, 
the induction and maintenance of adolescent OLZ sensitization 
and CLZ tolerance may involve the neuroplasticity initiated by 
D2/3 blockade in the above mentioned sites. This idea is con-
sistent with the findings showing that repeated administration 
of OLZ (5.0 mg/kg, once daily), but not CLZ (20.0 mg/kg, twice 
daily), from P 22–P 42 caused an increase of D2 receptor levels 
in the hippocampus and D4 levels in the NAc and caudate-pu-
tamen (CPu) in juvenile brains (Moran-Gates et al., 2006). Ap-
parently, actions on other neurotransmitter systems (e.g. sero-
tonergic, adrenergic, glutamatergic) in other brain areas during 
adolescence may also contribute to the long-lasting sensitiza-
tion and tolerance effects. Future work should systematically in-
vestigate the role of these receptors in the mediation of OLZ and 
CLZ tolerance from adolescence to adulthood. Furthermore, the 
contribution of pharmacokinetic differences between OLZ and 
CLZ (half-life: 2.5 h vs 1.5 h, respectively) (Kapur et al., 2003) to 
their different behavioral patterns may also need to be explored. 
Antipsychotic drugs are not only used to treat schizophre-
nia or schizoaffective disorders in children and adolescents, but 
also autism, attention deficit and hyperactivity disorder (ADHD), 
Tourette’s disorder, disruptive behaviors, bipolar disorder, and 
mood disorders (Correll et al., 2011). Because individuals with 
these disorders are likely to receive antipsychotic treatment upon 
becoming adults, the present work thus has implications for clin-
ical practice involving adolescent antipsychotic treatments, pro-
vided that the same sensitization or tolerance effect in healthy 
animals could be identified in human patients with schizophre-
nia who may already have some neuropathology at an early age, 
thus may respond to treatment differently from normal individu-
als. One lesson that can be learned from this preclinical study is 
that there is a possibility of long-term impacts of early antipsy-
chotic exposure on the brain and behavioral development and 
functions. Therefore, the choice of specific drug, drug dose and 
treatment schedule for individual patients needs to take their 
past treatment histories into consideration.   
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